期刊文献+

三阴性乳腺癌中EGFR、CK5/6的表达及临床意义 被引量:6

Expression and Clinical Significance of EGFR、CK5/6 in Triple Negative Breast Cancer
下载PDF
导出
摘要 目的:检测三阴性乳腺癌组织中EGFR、CK5/6的表达情况,探讨二者与三阴性乳腺癌患者临床与病理特征之间的关系。方法:回顾性分析94例三阴性乳腺癌患者的临床及病理资料,应用PV-9000免疫组化三步法检测EGFR、CK5/6在三阴性乳腺癌组织中的表达情况,分析二者与患者临床及病理指标之间的关系。结果:1EGFR、CK5/6在三阴性乳腺癌组织中的表达率分别为66.0%,74.5%;且二者的表达有关联性(r=0.287,P<0.05)。2EGFR的表达与年龄、肿瘤大小、组织学分级、民族、ki-67等临床及病理指标之间无统计学意义(P>0.05),在淋巴结有转移组及临床分期Ⅲ期组的表达率明显升高,差异有统计学意义(P<0.05);CK5/6的表达与淋巴结转移有关,而与其他临床病理指标无关,有淋巴结转移组CK5/6的表达率高于无转移组,差异有统计学意义(P<0.05)。结论:1在三阴性乳腺癌中,EGFR与CK5/6表达率高,二者表达趋于一致。2EGFR、CK5/6的高表达率与淋巴结转移有关,临床分期III期者EGFR阳性表达率高,二者可能与三阴性乳腺癌预后不良有关。 Objective:To detect the expression of EGFR,CK5/6 in triple negative breast cancer,furthermore to investigate their relationship with clinicopathological index. Methods:Expressions of EGFR,CK5/6 were detected in 94 cases of triple negative breast cacer tissues by PV-9000 immunohistochemical methods.Meanwhile,the relationship between the two indicators and clinicopathological index was analyzed. Results:(1)The expression of EGFR,CK5/6 in triple negative breast cacer were 66.0%,74.5% respectively.And expression of EGFR was correlation with CK5/6(r=0.287,P〈0.05), they have the same expression trend.(2)The expression of EGFR was no correlation with age,tumor size,histological grade,nation,expression of ki-67(P〉0.05), but it was much higher in?lymph node?metastasis group?and? clinical stageⅢ?group, the difference was statistically significant(P〈0.05),CK5/6 was related with lymph node metastasis, which ?expression in?lymph node?metastasis group was obviously higher than?non metastasis group(P〈0.05).Conclusion:(1) In the triple negative breast cancer, EGFR and CK5 / 6 showed high expression, and they have the same expression trend.(2) The expression of EGFR and CK5/6 were significantly related with lymph node metastasis,and EGFR also related with clinical stages, which indicates that they may be related to poor prognosis of triple negative breast cancer.
出处 《新疆医学》 2015年第1期13-16,共4页 Xinjiang Medical Journal
关键词 三阴性乳腺癌 EGFR CK5/6 Triple Negative Breast Cancer EGFR CK5/6
  • 相关文献

参考文献12

  • 1PEROU CM, SORLIE T, EISEN MB, et al. Molecu- lar portraits of human breast turnouts [J]. Nature, 2000;406(6797 ) :747-752.
  • 2SORLIE T,TIBSHIRANI R, PARKER J, et al. Re- peated observation of breast tumor subtypes in inde- pendent gene expression data sets [J]. Proe Natl A- cad Sci USA,2003 ; 100(14) :8418-8423.
  • 3SORLIE T,PEROU CM,TIBSHIRANI R,et al. Gene expression patterns of breast carcinomas dis- tinguish tumor subclasses with clinical implications [J]. Pine Natl Aead Sci USA, 2001,98 (19): 10869-1087.
  • 4GOLDHIRSCH A,WOOD WC,COATES AS,et al. Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St. Gallen Interna- tional Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J]. Ann Oncol,2011 ;22 (8): 1736-1747.
  • 5Nielsen TO, Hsu FD, Jensen K, et al.Immunohisto- chemical and clinica characterization of the basal-like subtype of invasive breast carcinoma I [J]. Clin Cancer Res, 2004; 10(16) : 5367-5374.
  • 6李艳艳,木扎帕尔.阿不都,孙刚,马斌林.267例乳腺浸润性导管癌EGFR、CK5/6表达分析[J].新疆医科大学学报,2013,36(3):316-319. 被引量:7
  • 7Nalwoga H, Ames JB, Wabinga H, et al. Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women [J].APMIS, 2008 ; 116 (6) : 515-525.
  • 8Pao W, Miller VA. Epidermal growth factor receptor mutations,small molecule kinase inhibitors,and non-small-cell lung cancer: current knowledge and future directions [J]. J Clin Oncol, 2005 ; 23 ( 11 ) : 2556-2568.
  • 9Siziopikou KP, Ariga R, Preussaloglou KE, et al. The challenging estrogen receptor-negative/progesterone reeeptor-negative/HER-2-negative patient: a promising candidate for epidermal growth factor re- ceptor-targeted therapy [J]. Breast J,2006; 12(4) : 360-362.
  • 10Mstos I, Dufloth R, Alvarenga M, et al. p63, cytok- eratin5 and P-eadherin:three molecular marks to distinguish basal phenotype in breast carcinomas [J]. Virehows Arch, 2005 ; 447 (4) : 688-694.

二级参考文献2

共引文献6

同被引文献49

  • 1中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2011版)[J].中国癌症杂志,2011,21(5):367-417. 被引量:269
  • 2Lehmann BD,Pietenpol JA.Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes[J].J Pathol,2014,232(2):142-150.
  • 3Galak.Chandarlapaty S.Molecular Pathways:HER3 Targeted Therapy[J].Clin Cancer Res,2014,20:14 10-1 416.
  • 4Moghal N,Sternberg PW.Multiple positive and negtive regulators ofSignaling by EGFR-recetor[J].Biology,1999,11(2):190.
  • 5Nielsen TO,Hsu FD,Jensen K,et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J].Clinal Cancer Res,2004,10:5 367-5 374.
  • 6Coley HM,ShottonCF,Ajose-Adeogun A,et al.Receptor tyrosine kinase(RTK)inhition is effective in chemosensitising EGFR-expressing drug resistant human overian cancer cell lines when used in comination with cytoxic agents[J].Biochem Phamacol,2006,72(8):941.
  • 7NozoeT.Immunohistochemical expression of epidemal growth factor receptor in breast cancer[J].Breast Cancer,2011,18(1):37-41.
  • 8Perez EA,Awada A,O’Shaughnessy J,et al.PhaseⅢtrial of etirinotecan pegol(EP)versus Treatment of Physician’s Choice(TPC)in patients(pts)with advanced breast cancer(aBC)whose disease has progressed following anthracycline(A),taxane(T)and capecitabine(C):The BEACON study[C],J Clin Oncol,2015,33(suppl a1001).
  • 9Traina TA,Miller K,Yardley DA,et al.Results from a phase 2study of enzalutamide(ENZA),an androgen receptor(AR)inhibitor,in advanced AR triple-negative breast cancer(TNBC)[C].J Clin Oncol,2015,33(suppla1003).
  • 10Li X,Zhou Q,Sunkara M.Ubiquitylation of phosphatidylinositol 4-phosphate 5-kinase type I gamma by HECTD1 regulates focal adhesion dynamics and cell migration[J].J Cell Sci,2013,126(12):2 617-2 628.

引证文献6

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部